Economic Evaluation of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure with Preserved or Mildly Reduced Ejection Fraction: A Systematic Review. | Synapse
Economic Evaluation of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Heart Failure with Preserved or Mildly Reduced Ejection Fraction: A Systematic Review.
Key Points
This evaluation aims to assess the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in patients with heart failure and varying ejection fraction.
Conducted a systematic review comparing SGLT2 inhibitors to standard of care.
Focused on patients with heart failure with preserved or mildly reduced ejection fraction.
Adding SGLT2 inhibitors to standard of care is cost-effective in the target population.
Further studies comparing dapagliflozin and empagliflozin are required.
Abstract
Study results indicate that adding SGLT2i to SoC is cost-effective in patients with HFpEF or HFmrEF. Moreover, further studies comparing dapagliflozin and empagliflozin in this patient group are needed.